PI  >> Vol. 6 No. 4 (September 2017)

    1 Case of Hepatic Injury Induced by Crizotinib

  • 全文下载: PDF(479KB) HTML   XML   PP.90-93   DOI: 10.12677/PI.2017.64015  
  • 下载量: 552  浏览量: 1,035  


胡 琴,王可武,张 涛:安徽省芜湖市第二人民医院,安徽 芜湖

克唑替尼药物性肝损伤肺癌Crizotinib Drug Liver Injury Lung Cancer


分析1例克唑替尼治疗ALK基因阳性非小细胞肺癌导致肝损伤,予以减量后仍然达到PR(部分缓解partial response)的疗效,提示我们临床诊疗应个体化对待。

Analysis of a case of the treatment of ALK gene positive non-small cell lung cancer caused liver injury by Crizotinib, and the effect of partial response was still achieved after reduction, suggesting that our clinical diagnosis and treatment should be individualized.

胡琴, 王可武, 张涛. 克唑替尼致肝损伤1例诊治经过[J]. 药物资讯, 2017, 6(4): 90-93. https://doi.org/10.12677/PI.2017.64015


[1] Doval, D., Prabhash, K., Patil, S., et al. (2015) Clinical and Epidemiological Studyof EGFR Mutations and EML4- ALK Fusion Genes among Indian Patients with Adenocarcinoma of the Lung. OncoTargets and Therapy, 5, 117-123.
[2] Gadgeel, S.M., Gandhi, L., Riely, G.J., et al. (2014) Safety and Activity of Alectinib against Systemic Disease and Brain Metastases in Patients with Crizotinib-Resistant ALK-Rearranged Non-Small-Cell Lung Cancer(AF-002JG): Results from the Dose-Finding Portion of a Phase 1/2 Study. The Lancet Oncology, 15, 1119-1128.
[3] Shaw, A.T., Kim, D.W., Nakagawa, K., et al. (2013) Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer. The New England Journal of Medicine, 368, 2385-2394.
[4] 毕国放, 梁宇光, 曲恒燕. 克唑替尼在非小细胞肺癌治疗中耐药问题的研究状况[J]. 中国临床药理学杂志, 2016, 32(10): 952-955.
[5] 宋玲玲, 刘红梅, 黄媚娟, 等. 克唑替尼治疗间变性淋巴瘤激酶阳性晚期非小细胞肺癌患者的临床疗效分析[J]. 华西医学, 2016, 31(1): 43-47.